Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01829256 · ClinicalTrials.gov registry record · NA
Simultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD)
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 285
- Enrollment target
NCT01829256 is a NA study that has completed, run by Duke University. The registered enrollment target is 285 participants.
The verdict
NCT01829256, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 285 participants
- Enrollment target
Study Summary
Diabetic kidney disease (DKD) is associated with high rates of cardiovascular events and death. In addition, DKD is the major cause of end-stage renal disease (ESRD) in the United States. The purpose of this study is to prevent progression of kidney disease among patients with DKD and uncontrolled hypertension (HTN) using a tailored, telehealth intervention that simultaneously address medication management and modifies multiple risk factors through a combination of patient self-monitoring, behavioral therapies and education to optimize adherence and self-efficacy. Additional goals are to improve control of cardiovascular disease risk factors and reduce cardiovascular events and death. We hypothesize that patients with DKD and uncontrolled HTN who receive this intervention will have less progression, or a smaller decrease in kidney function, after 3 years when compared to the education control group.
Interventions
- BEHAVIORAL Pharmacist telehealth intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2014-05 |
| Est. Completion | 2018-11-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01829256
The ClinicalTrials.gov registry entry for NCT01829256 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 285 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pharmacist telehealth intervention is the first listed.
NCT01829256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01829256 about?
NCT01829256 is a clinical study titled "Simultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD)". Diabetic kidney disease (DKD) is associated with high rates of cardiovascular events and death. In addition, DKD is the major cause of end-stage renal disease (ESRD) in the United States. The purpose of this study is to prevent progression of kidney disease among patients with DKD and uncontrolled h...
What is the current status of trial NCT01829256?
This trial is currently completed. It is a NA study. The enrollment target is 285 participants. The study started on 2014-05. Estimated completion is 2018-11-07.
What interventions are being tested in trial NCT01829256?
The interventions under investigation include: Pharmacist telehealth intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT01829256?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.